Treatment for chronic hepatitis C has evolved rapidly from an interferon based regimen of modest efficacy with significant adverse events to a well-tolerated, highly effective all-oral directly acting antiviral (DAA) therapy. It is the first DAA that has shown safety and efficacy to treat genotype 3 chronic HCV infections without the need for co-administration with interferon or ribavirin in most patients except cirrhosis. Daclatasvir, especially in combination with other antiviral agents such as sofosbuvir, is a very promising drug for the treatment of chronic hepatitis C in HCV genotype 3 patients This slide set gives an overview on the pharmacokinetics, efficacy, safety and place in therapy for daclatasvir- sofosbuvir combination in chronic hepatitis C.